Several brokerages have updated their recommendations and price targets on shares of Pacira Pharmaceuticals (NASDAQ: PCRX) in the last few weeks:

  • 8/4/2017 – Pacira Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/3/2017 – Pacira Pharmaceuticals was given a new $59.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/3/2017 – Pacira Pharmaceuticals had its price target lowered by analysts at BMO Capital Markets from $42.00 to $40.00. They now have a “market perform” rating on the stock.
  • 8/2/2017 – Pacira Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/2/2017 – Pacira Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company.
  • 7/31/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $56.00 price target on the stock.
  • 7/30/2017 – Pacira Pharmaceuticals was given a new $58.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 7/27/2017 – Pacira Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/26/2017 – Pacira Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $54.00 price target on the stock.
  • 7/25/2017 – Pacira Pharmaceuticals was given a new $56.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/19/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
  • 7/14/2017 – Pacira Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company. They wrote, “Nerve block data for Exparel is anticipated within the next month, and our consultants.””
  • 7/5/2017 – Pacira Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/27/2017 – Pacira Pharmaceuticals was given a new $58.00 price target on by analysts at Royal Bank Of Canada. They now have a “buy” rating on the stock.
  • 6/21/2017 – Pacira Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $87.00 price target on the stock.
  • 6/20/2017 – Pacira Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) traded up 0.41% on Tuesday, reaching $36.70. 1,356,317 shares of the company were exchanged. Pacira Pharmaceuticals, Inc. has a 12-month low of $29.95 and a 12-month high of $58.95. The stock’s market capitalization is $1.47 billion. The firm has a 50 day moving average price of $45.85 and a 200-day moving average price of $45.40.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.06. The company had revenue of $70.90 million during the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. Pacira Pharmaceuticals’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.21 EPS. On average, analysts predict that Pacira Pharmaceuticals, Inc. will post ($0.13) EPS for the current fiscal year.

In other news, CAO Kristen Marie Williams sold 1,877 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $43.32, for a total value of $81,311.64. Following the transaction, the chief accounting officer now owns 13,773 shares of the company’s stock, valued at approximately $596,646.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President James S. Scibetta sold 20,000 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $51.20, for a total transaction of $1,024,000.00. Following the completion of the transaction, the president now directly owns 47,084 shares in the company, valued at approximately $2,410,700.80. The disclosure for this sale can be found here. Insiders sold a total of 50,564 shares of company stock worth $2,506,682 in the last three months. Insiders own 6.60% of the company’s stock.

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Receive News & Ratings for Pacira Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.